68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study

Detalhes bibliográficos
Autor(a) principal: Cavicchioli,Marcelo
Data de Publicação: 2022
Outros Autores: Bitencourt,Almir Galvão Vieira, Lima,Eduardo Nóbrega Pereira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Radiologia Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842022000100013
Resumo: Abstract Objective: To compare 68Ga-DOTA-DPhe1,Tyr3-octreotate (68Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional 111In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs). Materials and Methods: This was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body 111In-octreotide scintigraphy and whole-body 68Ga-DOTATATE PET/CT. The patients had been referred for tumor staging (34.1%), tumor restaging (61.0%), or response evaluation (4.9%). Images were compared in a patient-by-patient analysis to identify additional lesions, and we attempted to determine the impact that discordant findings had on treatment planning. Results: Compared with 111In-octreotide scintigraphy, 68Ga-DOTATATE PET/CT revealed more lesions, the additional lesions typically being in the liver or bowel. Changes in management owing to the additional information provided by 68Ga-DOTATATE PET/CT occurred in five patients (12.2%), including intermodal changes in three (7.3%) and intramodal changes in two (4.9%). In addition, 68Ga-DOTATATE PET/CT yielded incidental findings unrelated to the primary NET in three patients (7.3%): Hürthle cell carcinoma of the thyroid, bowel non-Hodgkin lymphoma, and a suspicious breast lesion. Conclusion: We conclude that 68Ga-DOTATATE PET/CT is superior to conventional 111In-octreotide scintigraphy for the management of NETs because of its ability to determine the extent of the disease more accurately, which, in some cases, translates to changes in the treatment plan.
id CBR-1_35e1ae0088f28d4149fca5e3dc005eff
oai_identifier_str oai:scielo:S0100-39842022000100013
network_acronym_str CBR-1
network_name_str Radiologia Brasileira (Online)
repository_id_str
spelling 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective studyCarcinoma, neuroendocrine/diagnostic imagingPositron-emission tomography/methodsTomography, X-ray computed/ methodsRadionuclide imaging/methodsAbstract Objective: To compare 68Ga-DOTA-DPhe1,Tyr3-octreotate (68Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional 111In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs). Materials and Methods: This was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body 111In-octreotide scintigraphy and whole-body 68Ga-DOTATATE PET/CT. The patients had been referred for tumor staging (34.1%), tumor restaging (61.0%), or response evaluation (4.9%). Images were compared in a patient-by-patient analysis to identify additional lesions, and we attempted to determine the impact that discordant findings had on treatment planning. Results: Compared with 111In-octreotide scintigraphy, 68Ga-DOTATATE PET/CT revealed more lesions, the additional lesions typically being in the liver or bowel. Changes in management owing to the additional information provided by 68Ga-DOTATATE PET/CT occurred in five patients (12.2%), including intermodal changes in three (7.3%) and intramodal changes in two (4.9%). In addition, 68Ga-DOTATATE PET/CT yielded incidental findings unrelated to the primary NET in three patients (7.3%): Hürthle cell carcinoma of the thyroid, bowel non-Hodgkin lymphoma, and a suspicious breast lesion. Conclusion: We conclude that 68Ga-DOTATATE PET/CT is superior to conventional 111In-octreotide scintigraphy for the management of NETs because of its ability to determine the extent of the disease more accurately, which, in some cases, translates to changes in the treatment plan.Publicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem2022-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842022000100013Radiologia Brasileira v.55 n.1 2022reponame:Radiologia Brasileira (Online)instname:Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR)instacron:CBR10.1590/0100-3984.2021.0038info:eu-repo/semantics/openAccessCavicchioli,MarceloBitencourt,Almir Galvão VieiraLima,Eduardo Nóbrega Pereiraeng2022-02-07T00:00:00Zoai:scielo:S0100-39842022000100013Revistahttps://www.scielo.br/j/rb/https://old.scielo.br/oai/scielo-oai.phpradiologiabrasileira@cbr.org.br1678-70990100-3984opendoar:2022-02-07T00:00Radiologia Brasileira (Online) - Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR)false
dc.title.none.fl_str_mv 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
title 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
spellingShingle 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
Cavicchioli,Marcelo
Carcinoma, neuroendocrine/diagnostic imaging
Positron-emission tomography/methods
Tomography, X-ray computed/ methods
Radionuclide imaging/methods
title_short 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
title_full 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
title_fullStr 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
title_full_unstemmed 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
title_sort 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
author Cavicchioli,Marcelo
author_facet Cavicchioli,Marcelo
Bitencourt,Almir Galvão Vieira
Lima,Eduardo Nóbrega Pereira
author_role author
author2 Bitencourt,Almir Galvão Vieira
Lima,Eduardo Nóbrega Pereira
author2_role author
author
dc.contributor.author.fl_str_mv Cavicchioli,Marcelo
Bitencourt,Almir Galvão Vieira
Lima,Eduardo Nóbrega Pereira
dc.subject.por.fl_str_mv Carcinoma, neuroendocrine/diagnostic imaging
Positron-emission tomography/methods
Tomography, X-ray computed/ methods
Radionuclide imaging/methods
topic Carcinoma, neuroendocrine/diagnostic imaging
Positron-emission tomography/methods
Tomography, X-ray computed/ methods
Radionuclide imaging/methods
description Abstract Objective: To compare 68Ga-DOTA-DPhe1,Tyr3-octreotate (68Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional 111In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs). Materials and Methods: This was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body 111In-octreotide scintigraphy and whole-body 68Ga-DOTATATE PET/CT. The patients had been referred for tumor staging (34.1%), tumor restaging (61.0%), or response evaluation (4.9%). Images were compared in a patient-by-patient analysis to identify additional lesions, and we attempted to determine the impact that discordant findings had on treatment planning. Results: Compared with 111In-octreotide scintigraphy, 68Ga-DOTATATE PET/CT revealed more lesions, the additional lesions typically being in the liver or bowel. Changes in management owing to the additional information provided by 68Ga-DOTATATE PET/CT occurred in five patients (12.2%), including intermodal changes in three (7.3%) and intramodal changes in two (4.9%). In addition, 68Ga-DOTATATE PET/CT yielded incidental findings unrelated to the primary NET in three patients (7.3%): Hürthle cell carcinoma of the thyroid, bowel non-Hodgkin lymphoma, and a suspicious breast lesion. Conclusion: We conclude that 68Ga-DOTATATE PET/CT is superior to conventional 111In-octreotide scintigraphy for the management of NETs because of its ability to determine the extent of the disease more accurately, which, in some cases, translates to changes in the treatment plan.
publishDate 2022
dc.date.none.fl_str_mv 2022-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842022000100013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842022000100013
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0100-3984.2021.0038
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Publicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem
publisher.none.fl_str_mv Publicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem
dc.source.none.fl_str_mv Radiologia Brasileira v.55 n.1 2022
reponame:Radiologia Brasileira (Online)
instname:Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR)
instacron:CBR
instname_str Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR)
instacron_str CBR
institution CBR
reponame_str Radiologia Brasileira (Online)
collection Radiologia Brasileira (Online)
repository.name.fl_str_mv Radiologia Brasileira (Online) - Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR)
repository.mail.fl_str_mv radiologiabrasileira@cbr.org.br
_version_ 1754208941082935296